Felvizumab
Felvizumab
Felvizumab (pronounced: fel-viz-u-mab) is a monoclonal antibody designed for the treatment of Ebola virus disease. It is one of the many antibodies that have been developed to target and neutralize the Ebola virus.
Etymology
The name "Felvizumab" is derived from the International Nonproprietary Names (INN), where "mab" at the end signifies it as a monoclonal antibody. The prefix "Felvi" is a unique identifier for this specific antibody.
Usage
Felvizumab is used in the treatment of Ebola virus disease. It works by binding to the Ebola virus and neutralizing it, preventing the virus from entering and infecting the cells. This helps to control the spread of the virus in the body and aids in the recovery of the patient.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Felvizumab is a type of monoclonal antibody.
- Ebola virus disease: A severe, often fatal illness in humans caused by the Ebola virus. Felvizumab is used in the treatment of this disease.
- Antibody: A protein produced by the body's immune system when it detects harmful substances, called antigens. Felvizumab is a type of antibody.
- Ebola virus: A virus that causes Ebola virus disease. Felvizumab works by targeting and neutralizing this virus.
External links
- Medical encyclopedia article on Felvizumab
- Wikipedia's article - Felvizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski